Vaxcyte (PCVX) Change in Cash (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Change in Cash data on file, last reported at $86.9 million in Q1 2026.

• On a quarterly basis, Change in Cash rose 311.78% year-over-year to $86.9 million in Q1 2026; TTM through Mar 2026 was -$85.9 million, a 67.53% increase from a year earlier, with the FY2025 full-year figure at -$213.8 million, down 2184.11% from the prior year.
• Change in Cash for Q1 2026 stood at $86.9 million, up from -$107.1 million in the prior quarter.
• Over the last five years, Change in Cash for PCVX reached as high as $556.3 million in Q4 2022 and fell as low as -$662.3 million in Q4 2024.
• Historically, Change in Cash has averaged $11.3 million across 5 years, with a median of $14.3 million in 2023.
• Across the five-year window, Change in Cash sank 442.14% in 2023 and surged 3609.86% in 2024, its largest moves.
• Year by year, Change in Cash stood at $556.3 million in 2022, then plunged by 126.55% to -$147.7 million in 2023, then tumbled by 348.47% to -$662.3 million in 2024, then jumped by 83.83% to -$107.1 million in 2025, then surged by 181.11% to $86.9 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $86.9 million in Q1 2026, -$107.1 million in Q4 2025, and -$25.5 million in Q3 2025.